Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD) is a medical technology company that develops and markets at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. This news page aggregates company announcements, financial updates and clinical data releases related to TCMD stock and its underlying business.
Investors and healthcare observers can find earnings releases and quarterly financial results, where Tactile Medical reports revenue from its lymphedema and airway clearance product lines, along with metrics such as gross margin, operating income, net income and Adjusted EBITDA as defined by the company. These updates often include commentary on business priorities, share repurchase activity and outlook ranges for full-year revenue and Adjusted EBITDA.
The news flow also features clinical and scientific developments, including randomized controlled trial data on Flexitouch Plus for head and neck cancer-related lymphedema. Company press releases describe symptom improvements, swelling reduction and quality-of-life outcomes associated with its advanced pneumatic compression devices, as well as presentations at major medical meetings such as the American Society of Clinical Oncology and the American Congress of Rehabilitation Medicine.
In addition, this page includes notices of upcoming conference calls, investor conference presentations and other corporate events. Readers following TCMD news can use this feed to monitor how Tactile Medical communicates its strategy in at-home therapies, its collaboration with clinicians and durable medical equipment partners, and its efforts to expand access to care for patients with chronic lymphatic and pulmonary disorders. Bookmark this page for a centralized view of Tactile Systems Technology’s latest press releases and public disclosures.
Tactile Systems Technology (Nasdaq:TCMD), a medical technology company, announced participation in the Piper Sandler 34th Annual Healthcare Conference. The event will take place at the Lotte New York Palace on November 30, 2022, with a fireside chat scheduled for 1:30 p.m. Eastern Time. Investors can access a live audio webcast of the presentation on the company’s investor relations website, along with a replay following the event.
The company focuses on developing at-home therapies for chronic conditions like lymphedema, enhancing patient care and reducing healthcare costs.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) reported a 24% year-over-year increase in third quarter revenue to $65.3 million, up from $52.5 million. This revenue included $11.0 million from airway clearance products, largely due to the AffloVest acquisition. Despite a net loss of $2.3 million, improved profitability metrics were noted, with non-GAAP net income of $1.9 million. The company raised its full-year revenue guidance to $242 million to $245 million, reflecting ongoing growth and strong demand in their DME channel.
Tactile Systems Technology (Nasdaq:TCMD) announced that it will release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call will follow at 5:00 p.m. ET for an in-depth discussion of the results. Interested participants can join by dialing 877-407-3088 (international callers: 201-389-0927) with access code 13733034. The call will also be available via a live webcast on the company’s investor relations website. Tactile Medical focuses on developing at-home therapies for chronic conditions, improving patient care and reducing healthcare costs.
Tactile Systems Technology (Nasdaq: TCMD) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York City. The company's management will engage in a fireside chat on September 13 at 11:10 a.m. Eastern Time. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for replay post-conference. Tactile Medical focuses on at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease.
Tactile Systems Technology (TCMD) reported a 17% year-over-year revenue increase for Q2 2022, totaling $59.6 million. This growth was driven primarily by airway clearance product sales, which rose 96% from the previous year. Despite revenue growth, the company faced a net loss of $4.6 million compared to a net income of $1.3 million in Q2 2021, and operating expenses increased by 30%. The updated revenue guidance for 2022 is now set between $238 million and $242 million, reflecting an expected 14% to 16% growth.
Tactile Systems Technology (Nasdaq: TCMD) has announced the full market release of its new ComfortEase garments, enhancing the Flexitouch Plus system for lymphedema management. Developed from over 18,000 patient and therapist feedback, these garments aim to improve comfort, fit, and usability. Additionally, the company introduced the Kylee mobile app, assisting patients in health monitoring and symptom management. The app enables users to track their progress and engage with healthcare providers, reinforcing Tactile Medical's commitment to supporting patients with chronic conditions.
Tactile Systems Technology (Nasdaq: TCMD) will release its Q2 2022 financial results on August 1, 2022, after market close. The company specializes in medical devices for chronic diseases, providing at-home therapies for conditions like lymphedema and chronic venous insufficiency. A conference call will follow at 5:00 PM ET for discussion and a Q&A session. Interested parties can join by calling 877-407-3088 or via a live webcast on the investor relations website.
Tactile Systems Technology (Nasdaq: TCMD) announced a consensus statement highlighting the treatment of lymphedema, particularly secondary to chronic venous insufficiency (CVI). Published in Phlebology: The Journal of Venous Disease, the statement received endorsements from three independent professional societies. Key points include that pneumatic compression is recommended for lymphedema patients, and 92% of experts support its use. CEO Dan Reuvers emphasized the importance of addressing the estimated 20 million undiagnosed lymphedema cases in the U.S.
Tactile Systems Technology (Nasdaq: TCMD) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9, 2022, at the Loews Chicago Hotel. Management will present to investors on June 7 at 1:20 p.m. Central Time, followed by a breakout session. A live audio webcast will be available on the company’s investor relations website, with a replay accessible after the conference.
Tactile Medical specializes in developing at-home therapies for chronic conditions like lymphedema and chronic pulmonary disease, aiming to improve patient care and reduce healthcare costs.
Tactile Systems Technology (Nasdaq: TCMD) reported a 12% increase in revenue for Q1 2022, totaling $48.0 million, up from $42.8 million in Q1 2021. Revenue included $7.3 million from airway clearance products, notably the AffloVest product line. However, the company faced significant challenges with an operating loss of $14.9 million and a net loss of $15.6 million, compared to losses of $4.1 million and $2.3 million respectively in Q1 2021. The company reaffirmed its 2022 revenue guidance of $235 million to $240 million, a growth of 13% to 15% year-over-year.
FAQ
What is the current stock price of Tactile Systems (TCMD)?
What is the market cap of Tactile Systems (TCMD)?
